Dangerous unintended consequences that hamper vital (medical) innovation

Decision-Making

A second, ironic, problem is that companies fear that if they produce a truly vital technology, governments will lean on them to relinquish their patent rights or slash prices. This was the fate of Bayer, the manufacturer of the anthrax treatment Cipro, when an unknown terrorist began mailing anthrax spores in late 2001, killing five people. Four years later, as anxiety grew about an epidemic of bird flu in humans, the owner of the patent on Tamiflu, Roche, agreed to license production of the drug after very similar pressure from governments across the world. It is quite obvious why governments have scant respect for patients in true emergencies. Still, if everybody knows that governments will ignore patents when innovations are most vital, it is not clear why anyone expects the patent system to encourage vital innovations.

A lifesaving treatment creates the strongest case for public access and the nastiest incentive problem for future research. Once the emergency arrives, “protect the patent” can sound morally obscene. Announce in advance that exceptional usefulness will erase expected returns, however, and uncertain research becomes harder to finance. Both truths can occupy the room. Policy slogans generally invite one in and leave the other outside with security.

Medicine makes the stakes brutal, but the design question is familiar: who carries risk before success, who gains after it, and what happens when private reward collides with public need? Patents, licensing, prizes, public funding and advance purchase commitments distribute that bargain differently. None deserves religious devotion. Nor should a company receiving public help expect every later gain to remain private. The important work happens before crisis compresses every disagreement into a moral emergency. Define intervention conditions, compensation, production rights and public obligations while negotiation can still use daylight. Predictability gives governments tools for access and researchers a risk they can price rather than a surprise they must fear.

Good intentions after discovery cannot compensate for rules that discouraged the discovery beforehand. A system should make vital innovation worth attempting and vital treatment possible to obtain. Anyone promising that one tidy lever delivers both without trade-offs is selling policy by PowerPoint.